Loading…

Nanovaccine Showing Potent Immunotherapy to Tumor by Activating Γ δ T Cells

Most vaccines are designed to attack tumor cells by activating CD4 + /CD8 + αβ T cells. Unfortunately, αβ T cells, which only recognize the peptide antigens in the complexes with polymorphic MHCI/II molecules, surrender to the tumor heterogenicity. As another subset of T cells, γδ T cells become sal...

Full description

Saved in:
Bibliographic Details
Published in:Advanced functional materials 2023-10, Vol.33 (44)
Main Authors: Yang, Zeyu, Li, Liyan, Wei, Chengxiu, Liu, Hong, Qiao, Dongdong, Wen, Zhenfu, Chen, Haolin, Huang, Shanghui, Guo, Rui, Yin, Zhinan, Liu, Lixin, Chen, Yongming
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most vaccines are designed to attack tumor cells by activating CD4 + /CD8 + αβ T cells. Unfortunately, αβ T cells, which only recognize the peptide antigens in the complexes with polymorphic MHCI/II molecules, surrender to the tumor heterogenicity. As another subset of T cells, γδ T cells become salient in antitumor because of their unique immunotherapeutic roles. Herein, a tumor vaccine is developed with multivalent antigens by fusion of tumor cell membranes with lipids and successfully activated γδ T cells via microneedle inoculation. It is certified that the evoked γδ T cells synchronize with αβ T cells revitalizing tumor‐induced immunotolerance. In turn, the tumors of mice are significantly inhibited and their median survival time is prolonged considerably. Moreover, the nanovaccine inhibits tumor recurrence after resection. The therapeutic effects are corroborated with the results from TCR δ −/− mice as well as cytokine expression in tumor.
ISSN:1616-301X
1616-3028
DOI:10.1002/adfm.202303537